{"count": 2, "results": [{"_id": "33002553", "pmid": 33002553, "title": "Comparative clinical study evaluating the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin therapy on diabetic patients with symptomatic coronary artery disease.", "journal": "Diabetes Res Clin Pract", "authors": ["Werida R", "Kabel M", "Omran G", "Shokry A", "Mostafa T"], "date": "2020-12-01T00:00:00Z", "doi": "10.1016/j.diabres.2020.108473", "meta_date_publication": "2020 Dec", "meta_volume": "170", "meta_issue": "", "meta_pages": "108473", "score": 50244.527, "text_hl": "RESULTS: Three months after intervention and as compared to group II (@CHEMICAL_glimepiride @CHEMICAL_MESH:C057619 @@@Glimepiride@@@/@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@), group 1 (@CHEMICAL_Vildagliptin @CHEMICAL_MESH:D000077597 @@@Vildagliptin@@@/@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@) showed significantly lower BMI (28.73 +- 3.48 versus 30.55 +- 3.15; p = 0.02), HbA1c (6.05 +- 0.72 versus 7.06 +- 0.89; p < 0.0001), hsCRP (0.96 +- 0.20 versus 1.72 +- 0.38; p < 0.0001), @GENE_IL1B @GENE_3553 @@@IL-1beta@@@ (34.95 +- 10.01 versus 45.13 +- 10.26; p < 0.0001), @<m>DISEASE_275350</m> @DISEASE_OMIM:275350 @@@TC@@@ (136 +- 23.45 versus 169 +- 35.72; p < 0.0001), @CHEMICAL_Thioguanine @CHEMICAL_MESH:D013866 @@@TG@@@ (116 +- 29.10 versus 146 +- 56.58; p = 0.005), and CRI (2.47 +- 0.90 versus 3.65 +- 1.19; p < 0.0001) which was associated with significantly higher @GENE_ADIPOQ @GENE_9370 @@@adiponectin@@@ and HDL-C (4.42 +- 1.29 versus 2.52 +- 1.86; p < 0.0001 and 61 +- 23.04 versus 48 +- 12.92; p = 0.003 respectively). ", "citations": {"NLM": "Werida R, Kabel M, Omran G, Shokry A, Mostafa T. Comparative clinical study evaluating the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin therapy on diabetic patients with symptomatic coronary artery disease. Diabetes Res Clin Pract. 2020 Dec;170():108473. PMID: 33002553", "BibTeX": "@article{33002553, title={Comparative clinical study evaluating the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin therapy on diabetic patients with symptomatic coronary artery disease.}, author={Werida R and Kabel M and Omran G and Shokry A and Mostafa T}, journal={Diabetes Res Clin Pract}, volume={170}, pages={108473}}"}}, {"_id": "22639397", "pmid": 22639397, "title": "Statin is a reasonable treatment option for patients with Polycystic Ovary Syndrome: a meta-analysis of randomized controlled trials.", "journal": "Exp Clin Endocrinol Diabetes", "authors": ["Gao L", "Zhao FL", "Li SC"], "date": "2012-06-01T00:00:00Z", "doi": "10.1055/s-0032-1304619", "meta_date_publication": "2012 Jun", "meta_volume": "120", "meta_issue": "6", "meta_pages": "367-75", "score": 50051.86, "text_hl": "Meanwhile, statin was more effective than placebo in reducing LDL (WMD=- 0.87, 95%CI - 1.18~ - 0.55, P<0.0001), @<m>DISEASE_275350</m> @DISEASE_OMIM:275350 @@@TC@@@ (WMD=- 1.23 95%CI - 1.35~ - 1.11, P<0.00001), TG (WMD= - 0.50, 95%CI - 0.73~ - 0.27, P<0.00001); and statin + @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ was more effective than @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ in lowering LDL (WMD= - 0.84, 95%CI: - 1.33 ~ - 0.354, P=0.0009), @<m>DISEASE_275350</m> @DISEASE_OMIM:275350 @@@TC@@@ (WMD= - 1.28, 95%CI: - 1.47 ~ - 1.10, P<0.00001), and TG (WMD= - 0.27, 95%CI: - 0.36~ - 0.19, P<0.00001). ", "citations": {"NLM": "Gao L, Zhao FL, Li SC. Statin is a reasonable treatment option for patients with Polycystic Ovary Syndrome: a meta-analysis of randomized controlled trials. Exp Clin Endocrinol Diabetes. 2012 Jun;120(6):367-75. PMID: 22639397", "BibTeX": "@article{22639397, title={Statin is a reasonable treatment option for patients with Polycystic Ovary Syndrome: a meta-analysis of randomized controlled trials.}, author={Gao L and Zhao FL and Li SC}, journal={Exp Clin Endocrinol Diabetes}, volume={120}, number={6}, pages={367-75}}"}}]}